相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retained duplications and deletions of CYP2C genes among primates
Morgan E. Chaney et al.
MOLECULAR PHYLOGENETICS AND EVOLUTION (2018)
Widespread Use of Prescription Nonsteroidal Anti-Inflammatory Drugs Among US Army Active Duty Soldiers
Leila A. Walker et al.
MILITARY MEDICINE (2017)
Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System
Tilo Grosser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
Yun-Jeong Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers
Dolores Ochoa et al.
PHARMACOGENOMICS (2015)
CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug Dosing-A Correlation Analysis Using Flurbiprofen as Probe Drug
Silvia Vogl et al.
PLOS ONE (2015)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
K. E. Caudle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general US population
Yingjun Zhou et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals
Hye-In Lee et al.
PHARMACOGENETICS AND GENOMICS (2014)
Individual NSAIDs and Upper Gastrointestinal Complications
Jordi Castellsague et al.
DRUG SAFETY (2013)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
N. Bhala et al.
LANCET (2013)
Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam
Chang-Ik Choi et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2011)
Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use
T. Gorski et al.
BRITISH JOURNAL OF SPORTS MEDICINE (2011)
Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction A Nationwide Cohort Study
Anne-Marie Schjerning Olsen et al.
CIRCULATION (2011)
Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga
Tilo Grosser et al.
ANNUAL REVIEW OF MEDICINE (2010)
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Jonatan D. Lindh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data
Makiko Kusama et al.
PHARMACEUTICAL RESEARCH (2009)
Global variation in CYP2C8-CYP2C9 functional haplotypes
William C. Speed et al.
PHARMACOGENOMICS JOURNAL (2009)
The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction
John S. Brownstein et al.
PLOS ONE (2007)
The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery
Maarten J. Beinema et al.
MOLECULAR DIAGNOSIS & THERAPY (2007)
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
A. Lanas et al.
GUT (2006)
Effect of Celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas
Scott D. Solomon et al.
CIRCULATION (2006)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Allelic variants of cytochrome P4502C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants
LE Visser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
YJ Guo et al.
DRUG METABOLISM AND DISPOSITION (2005)
Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population
C Huerta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Cytochrome P4502C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient
D Stempak et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication
H Malhi et al.
POSTGRADUATE MEDICAL JOURNAL (2004)
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P4502C8 and 2C9 amino acid polymorphisms
E García-Martín et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype
KN van Dijk et al.
THROMBOSIS AND HAEMOSTASIS (2004)
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
J Kirchheiner et al.
PHARMACOGENETICS (2003)
Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes
CR Lee et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data
CR Lee et al.
PHARMACOGENETICS (2002)
分享论文
